Ophthalmic Consultants of Long Island
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ophthalmic Consultants of Long Island sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Ophthalmic Consultants of Long Island: 6 sponsored US clinical trials, 1 recruiting.
Ophthalmic Consultants of Long Island sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 4 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Patient Preference, with 1 trials.
Upper-quartile sponsor footprint
Ophthalmic Consultants of Long Island sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery
NCT04205916
Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study
NCT01813773
Diurnal Variation in Tear Osmolarity
NCT01321424
Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
NCT00799682
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
NCT00407043
Efficacy of Topical Cyclosporin for Ocular Rosacea
NCT00348335
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
Where Ophthalmic Consultants of Long Island enrollment is open (later-stage tilt)
1 recruiting of 6 indexed (17% open); 5 completed (83%).
Phase mix: 4 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Patient Preference (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ophthalmic Consultants of Long Island: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Ophthalmic Consultants of Long Island sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Ophthalmic Consultants of Long Island page
6 registered trials is a research-attention snapshot, not an endorsement of Ophthalmic Consultants of Long Island or any single study.
- 1 of Ophthalmic Consultants of Long Island's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Patient Preference is the condition Ophthalmic Consultants of Long Island studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Patient Preference trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ophthalmic Consultants of Long Island pipeline card: 6 registered trials from official public datasets.Report a data error.